TileBio
3 known investors
Find your way into TileBio
153 people in our graph share verified history with the TileBio team — schools, employers, funds. One of them is your warm intro.
David Maherunlockedknows David Chang · together at UNSW (overlapped)
×4knows the team · via University of Sydney
×5knows the team · via UNSW
×2knows the team · via University of Glasgow
TileBio develops self-supervised AI foundation models for digital pathology, applied to cancer diagnosis, prognosis, biomarker discovery, and drug development. It serves clinicians, diagnostics, and pharmaceutical research by analysing pathology imaging and sequencing data.
Founders & leadership
CW
Christopher WalshCo-Founder / CEO & CTO
KY
Ke YuaninCo-Founder / CSO
DC
David ChanginCo-Founder / CMOHe holds a PhD in Medicine focused on pancreatic cancer from UNSW and brings expertise in genomics, transcriptomics, and molecular oncology from prior academic and research roles.
JL
John Le QuesneinCo-Founder / CMOJohn Le Quesne is a clinician-scientist and histopathologist who leads a spatial biology facility at the CRUK Scotland Institute. He co-founded TileBio, a University of Glasgow spinout developing AI foundation models for computational pathology and precision cancer diagnostics.
Investors · 3
Also in the syndicate · 1
GU Holdings Ltd
Funding
SEC filings, press & company announcements- Undisclosed amountseedMar 2026
Twin Path Ventures (lead), GU Holdings Ltd, Scottish Enterprise
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 6
by search overlapTellBio5 shared keywordsTellBio is a biotechnology company founded by leading cancer researchers and clinicians from Harvard Medical School and Massachusetts General Hospital. The company focuses on oncology research and development, leveraging circulating tumor cell (CTC) technology and biomedical engineering.
GentiBio4 shared keywordsGentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.
ChronicleBio3 shared keywordsTechbio company using multi-omic biobank data and AI to stratify patients with POTS, ME/CFS, Long COVID and other neuroimmune conditions.
TELA Bio3 shared keywordsOffers soft tissue repair solutions combining naturally sourced tissue with polymer; lead product OviTex for hernia repair (NASDAQ: TELA), based in Malvern, PA.
Talus Bio3 shared keywordsTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Manifold3 shared keywordsManifold Bio combines AI-guided protein design with high-throughput in vivo screening to engineer tissue-targeted biologics and deliver therapeutic payloads to specific organs. The company develops a computational and experimental platform to optimize pharmacokinetics and biodistribution directly in living systems for drug discovery and development.
Companies competing with TileBio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does TileBio do?
- TileBio develops self-supervised AI foundation models for digital pathology, applied to cancer diagnosis, prognosis, biomarker discovery, and drug development. It serves clinicians, diagnostics, and pharmaceutical research by analysing pathology imaging and sequencing data.
- Who founded TileBio?
- TileBio was founded by Christopher Walsh, Ke Yuan, David Chang, John Le Quesne.
- Who are TileBio's investors?
- TileBio's investors include Twin Path Ventures, Scottish Enterprise.